Omalizumab in chronic spontaneous urticaria treatment: Real life experiences
TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, vol.53, no.4, pp.145-149, 2019 (ESCI, Scopus, TRDizin)
- Publication Type: Article / Article
- Volume: 53 Issue: 4
- Publication Date: 2019
- Doi Number: 10.4274/turkderm.galenos.2019.90001
- Journal Name: TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY
- Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
- Page Numbers: pp.145-149
- Istanbul University-Cerrahpasa Affiliated: Yes
Abstract
Background and Design: Urticaria is an intensely pruritic dermatologic disorder characterized by temporary erythematous and edematous lesions. Immunoglobulin E (IgE), mast cells, and histamine play a major role in its pathogenesis. H-1 antihistamines are the basis of the treatment, but they may not be sufficient for some cases. The latest guidelines advise using omalizumab, anti-IgE monoclonal antibody, for patients with refractory urticaria. Our aim was to evaluate the efficacy and safety of omalizumab in patients with chronic spontaneous urticaria and share the real-life experiences in our patients.